

Tabla 4: Actividad *in vitro* de fluoroquinolonas contra anaerobios.

Bacteria	Ciprofloxacina		Clinafloxacin		Garenoxacina		Gatifloxacina		Gemifloxacina		Grepafloxacina		Levofloxacina		Moxifloxacina		Sitafloxacina		Sparfloxacina		Trovafloracina	
	CIM ₅₀	CIM ₉₀	CIM ₅₀	CIM ₉₀	CIM ₅₀	CIM ₉₀	CIM ₅₀	CIM ₉₀	CIM ₅₀	CIM ₉₀	CIM ₅₀	CIM ₉₀	CIM ₅₀	CIM ₉₀	CIM ₅₀	CIM ₉₀	CIM ₅₀	CIM ₉₀	CIM ₅₀	CIM ₉₀	CIM ₅₀	CIM ₉₀
<i>Bacteroides fragilis</i>	4	16	0.25	1	0.125	0.25	0.5	1	0.5	2	2	16	2	8	0.25	1	0.06	0.25	1	2	0.25	0.5
<i>Bacteroides fragilis</i> group	8	32	0.12	0.25	1	8	1	4	1	4	2	4	2	16	0.5	1	0.12	1	2	4	0.5	1
<i>Clostridium difficile</i>	8	16	0.25	1	1	1	1	2	1	8	16	32	4	8	1	2	0.25	0.5	4	8	1	8
<i>Clostridium perfringens</i>	0.5	1	0.12	0.12	0.5	1	0.5	0.5	0.06	0.12	0.25	0.5	0.5	1	0.5	0.5	0.06	0.06	0.25	0.5	0.25	0.25
<i>Fusobacterium</i> spp.	2	8	0.06	0.25	0.25	2	1	1	0.25	2	2	8	0.5	4	0.12	0.5	0.25	0.5	2	4	0.5	4
<i>Peptostreptococcus</i> spp.	1	4	0.12	0.25	0.03	0.06	0.25	1	0.12	0.12	0.5	1	0.5	2	0.25	0.5	0.03	0.12	0.5	1	0.25	1

CIM₅₀ = concentración inhibitoria mínima (µg/ml) del 50% de los cultivos, CIM₉₀ = concentración inhibitoria mínima del 90% de los cultivos, n.d. = información no disponible.

Puntos de corte aprobados y tentativos del *National Committee for Clinical Laboratory Standards*: [121].

1. *B. fragilis*: trovafloracina ≥ 8 µg/ml es resistente y no hay información disponible para el resto.

La información presentada en la Tabla fue adaptada de las referencias: ciprofloxacina: [34,48,51,58,82,83,85,97,128,129,147,150,172]; clinafloxacin: [30,48,69,82,85,95]; garenoxacina: [69,98,103,120,131,134]; gatifloxacina: [34,57,85,97,128,147]; gemifloxacina: [48,82,85,90,133]; grepafloxacina: [48,85,97,133]; levofloxacina: [57,58,69,72,82,85,97,127,129,133,134,150]; moxifloxacina: [42,48,58,83,113,114,127,134,135]; sitafloxacina: [58,130,133,135]; sparfloxacina: [42,51,57,91,128,133]; trovafloracina: [42,48,51,58,72,82,85,118,128,129,132,133,147].